Novel Assay Provides 100 Times More Information Than Current Liquid Biopsies for Early Cancer Detection

August 2017, Vol 10, Special Issue: Payers’ Perspectives in Oncology: ASCO 2017 Highlights - Emerging Therapies
Phoebe Starr

Chicago, IL—A new high-intensity genomic sequencing strategy (developed by Grail Inc) detects circulating tumor DNA (ctDNA) at a high rate. The new approach is a major improvement on previous tests using ctDNA, which focus on a limited number of driver mutations to inform treatment strategies for metastatic disease or to monitor disease burden. The new test offers ultra-deep sequencing with a broad genomic coverage, but it is not ready for prime time to detect occult cancer. At present, the test is a research platform and is not commercially available.

“This approach offers an unprecedented combination of breadth and depth, covering about 508 genes and yielding 100 times more data than other approaches,” said lead investigator Pedram Razavi, MD, PhD, Medical Oncologist, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York City, during the 2017 ASCO annual meeting.

“Our findings show that high-intensity ctDNA sequencing is possible and may provide invaluable information for clinical decision-making, potentially without the need for tumor tissue samples. The ultimate goal would be to detect cancer in early, treatable stages,” he told attendees at the press conference.

Dr Razavi presented the results of a concordance study in 124 patients with metastatic breast cancer, non–small-cell lung cancer, or castration-resistant prostate cancer.

Comparing plasma and tissue samples, the new test was able to detect 89% of genetic changes that had been identified with regular tumor biopsy and 76% of “actionable” mutations amenable to currently available targeted therapy.

“A high level of concordance was seen for variants between plasma and tissue, providing strong evidence for high rates of tumor DNA detection in plasma,” Dr Razavi explained. “The breadth of detected variants in plasma ctDNA enables greater insight into tumor biology, including the first exploration of mutational signature analysis in plasma,” he added.

Experts Comment on Early Data

At the press conference, ASCO experts agreed that this technology is still in its early days. “We continue to see promising reports about the possible uses of circulating tumor DNA analysis. While this approach has a way to go before it becomes a proven technology for early cancer detection, this research is an important first step,” said John V. Heymach, MD, PhD, Chairman, Department of Thoracic/Head and Neck Medical Oncology, M.D. Anderson Cancer Center, Houston.

Related Items
Chemotherapy Can Be Spared in Many Patients with Early Breast Cancer: Devil Is in the Details
Phoebe Starr
August 2018 Vol 11, Special Issue published on August 20, 2018 in Breast Cancer
Less Is More: 6 Months of Trastuzumab Treatment Equivalent to 12 Months in HER2-Positive Breast Cancer
Phoebe Starr
August 2018 Vol 11, Special Issue published on August 20, 2018 in Breast Cancer
Immunotherapy Combinations "Raising the Bar"
Phoebe Starr
August 2018 Vol 11, Special Issue published on August 20, 2018 in Immunotherapy
Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation
Phoebe Starr
August 2018 Vol 11, Special Issue published on August 20, 2018 in Emerging Therapies
LOXO-292 Highly Effective in RET-Positive Cancers
Chase Doyle
August 2018 Vol 11, Special Issue published on August 20, 2018 in Emerging Therapies
Last modified: August 24, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME